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receiving verbal and written details regarding the procedures adopted
in the study, whichwas approved by the Ethics Committee of the Feder-
al Fluminense University (protocol approval number 384.150/2013).
Preparation of 99mTc-MDP and 99mTc-DPD and quality control were
made in accordance with instructions provided by the manufacturers
in package inserts. Each patient was administered 740 MBq of 99mTc-
DPD and 99mTc-MDP intravenously, and anterior and posterior whole-Hereditary transthyretin-related amyloidosis (ATTR) is themost fre-
quent form of familial systemic amyloidoses, a group of severe diseases
with neurological and polyvisceral involvement [1]. Cardiac involve-
ment is a major cause of morbidity and mortality [2]. The discovery of
tests that allow early diagnosis of cardiac involvement in amyloidosis
is very important because these patients require strict follow-up.
99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid (99mTc-DPD)
scintigraphy has proved to be useful in differential diagnosis between
TTR (both mutant and wild-type) and immunoglobulin light chain
(AL) etiologies in patients with echocardiographically deﬁned cardiac
amyloidosis [3].
99mTc-MDP seems to have lower sensitivity than 99mTc-DPD for de-
tecting cardiac amyloidosis, especially in the hereditary form related
protein transthyretin [2]. Little is known whether the use of 99mTc
DPD is superior to 99mTc-MDP in the detection of asymptomatic cardiac
involvement in patients with familial amyloidosis. We conducted this
comparative study in patients with proven amyloidosis and in their
relatives to assess which of the two radiopharmaceuticals are more
accurate in the early detection of cardiac amyloid involvement.
The patients were recruited from the Neurology Outpatient Clinic in
Antônio Pedro University Hospital and from the Brazilian Association of
Amyloidosis by phone/electronic contact. Eligibility criteria involved
(1) age ≥18 years, (2) signed consent form and (3) the status of amy-
loidosis or ﬁrst-degree relatives' DNAmutation carriers. Diagnosis of fa-
milial TTR-related amyloidosis was deﬁned by a documented TTR
mutation at DNA analysis [4]. We excludedwomenwhowere pregnant
or with suspected pregnancy. The patients were submitted to two sep-
arate scintigraphic images with a minimum interval of 72 h to evaluatece, Department of Radiology,
niversity, Dr. Paulo Cesar, 155,
ira).
.cardiac amyloid deposit. Eligible patients provided a consent form after
body images and selective images in anterior, 45° left anterior oblique,
and left lateral projections were obtained 3 h later. Two observers
from the nuclear medicine service with extensive experience in the
evaluation of cardiology studies analyzed the resulting gray-scale
images visually. Discrepancies were resolved by consensus. The in-
tensity of the uptake was scored according to Rappezzi et al. seen
using a semi-quantitative visual scale [1]. Cardiac amyloidosis was
echocardiographically deﬁned as end-diastolic thickness of the in-
terventricular septum N1.2 cm (in the absence of any other plausible
cause of ventricular hypertrophy) [5]. Independence of categorical var-
iableswas tested using Fisher exact test or Pearson chi-square test. Con-
tinuous variables were analyzed using Mann–Whitney U test. Values of
p b0.05 were considered signiﬁcant.
We recruited 19 subjects (11 female),mean age of 41.3±13.9 years.
Eighteen patients underwent two scans; one patient underwent 99mTc-
MDP but refused to carry on the 99mTc-DPD scintigraphy (Table 1). Nei-
ther 99mTc-DPD nor 99mTc-MDP scintigraphy revealed an appreciable
deposition in the cardiac region (score of 0) in any of the patients who
had a normal echocardiogram, except one that had abnormal strain
rate (patient number 5 in Table 1). Two patients were diagnosed with
cardiac amyloidosis deﬁned by echo criteria: one had intense 99mTc-
DPD uptake (score of 2–3) andmild 99mTc-MDP uptake in the cardiac re-
gion and the other had nouptake of any tracer. In Fig. 1we depicted a pa-
tient with cardiac uptake of DPD Grade 3 and MDP Grade 0. There were
three additional patients that had abnormal strain rate by echo but did
not have radiotracer uptake in the cardiac region. Using traditional echo-
cardiographic criteria for diagnosing cardiac amyloidosis the sensitivity
of DPD was 50% and speciﬁcity was 94%. Interestingly, nuclear medicine
was positive in one patient that did not have left ventricular hypertrophy
but had atrioventricular block, suggesting an association of DPD uptake
and conduction disturbances without hypertrophy.
Our ﬁndings suggest that 99mTc-DPD is a better imaging tracer for
the diagnosis of ATTR because it binds preferentially to cardiac amyloid,
Table 1
Demography and imaging ﬁndings in subjects studied.
Patient Sex Age Echo
positive
Mutation Score
99mTc-MDP
Score
99mTc-DPD
1 F 41 N val122Ile 0 0
2 F 64 LVH val30met 1 3
3 M 31 N val30met 0 0
4 F 33 LVH val30met 0 0
5 M 54 AST val30met 1 2
6 F 31 N val30met 0 0
7 M 60 N val30met 0 0
8 F 56 N NA 0 0
9 F 21 N NA 0 0
10 M 38 N val30met 0 0
11 F 36 N val30met 0 0
12 M 39 AST val30met 0 0
13 M 45 N val30met 0 0
14 F 22 N val30met 0 0
15 F 59 AST val30met – 0
16 M 52 AST NA 0 0
17 F 25 N NA 0 0
18 F 31 N val30met 0 0
19 M 35 N val30met 0 0
Uptake intensity was graded according to a visual scale ranging from 0 to 3 points, in
which the absence of uptake was assigned a value of 0 points: uptake less than that ob-
served in bone (referred to as the adjacent rib), 1 point; uptake similar to that of bone, 2
points; and uptake greater than that of bone, 3 points.
Fig. 1. Comparison of 99mTc-DPD and 99mTc-MDP scintigraphy in a cardiac amyloidosis conﬁ
886 Correspondencewithmore avidity than 99mTc-DPD. However, 99mTc-DPD cannot replace
echocardiography because of its low sensitivity, being complementary
as demonstrated by the ﬁnding of abnormal uptake in a patient with
normal echocardiographic exam. The ﬁrst description involving the
use of DPD in amyloidosis was performed by De Haro et al., where a
patient with amyloidosis AL type (for immunoglobulin light chains)
showed uptake in heart projection, parotid gland, uterus and gastroin-
testinal tract [6]. In 2002, Puille et al. [7] have shown for the ﬁrst time
in 8 patients with ATTR, abnormal uptake of DPD in the heart. These
authors concluded that although not deﬁnitive, 99mTc-DPD uptake in
the heart of a patient with systemic amyloidosis strongly suggests
ATTR disease [7].
Hutt et al. [3] studied the utility and limitations of 99mTc-DPD
scintigraphy in the greatest series of patients with suspected cardiac
amyloidosis (321 patients). All 158 patients with ATTRwith clinical car-
diac involvement had cardiac 99mTc-DPD uptake, with median Grade 2
intensity, however 18 of 35 (51%) AL patients with cardiac involvement
had 99mTc-DPD cardiac uptake too (median Grade 1 intensity). Taken
together these data suggest that 99mTc-DPD scintigraphy is a highly sen-
sitive technique for imaging cardiac ATTR but it is not speciﬁc for ATTR
in isolation [3]. Our ﬁndings are in accordance with Hutt [3] data
because we found one patient with ATTR and 99mTc-DPD cardiac uptake
but without echocardiographic hypertrophy. In their study 13 ATTR pa-
tientswithout clinical evidence of cardiac involvement also demonstratedrmed patient. There is abnormal uptake in cardiac region more intense in DPD image.
887Correspondence99mTc-DPD cardiac uptake [3]. We may speculate that speckle tracking
imaging may detect earlier cardiac involvement and can correlate better
with DPD uptake in these patients [8].
In conclusion, 99mTc-DPD is a better imaging tracer for the diagnosis
of ATTR than 99mTc-MDP. The role of 99mTc-DPD scintigraphy on dis-
crimination of familial cardiac amyloidosis is complementary to other
imaging techniques, especially echocardiography.
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